Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corvus Pharmaceuticals reports Q4 loss, highlights CPI-818 potential and challenges

Corvus Pharmaceuticals showcased a mixed financial performance with a focus on managing cash burn rate and extending cash runway.
The company's strength lies in the potential of CPI-818 in various indications and the identification of a patient selection biomarker.
Challenges include cash management, regulatory hurdles in upcoming trials, and the need for clarity on biomarker validation.
Opportunities abound in market expansion, clinical development acceleration, and strategic initiatives for growth and value creation.

Corvus Pharmaceuticals reports Q1 progress with CPI-818 advancements

Corvus Pharmaceuticals reported financial improvements and progress in CPI-818 development.
Partnerships and upcoming trials indicate a promising future for the company.
Challenges lie in addressing analyst queries and ensuring trial success and data presentation.

Corvus Pharmaceuticals reports Q2 progress in cancer drug trials

Corvus Pharmaceuticals reported improved financials with reduced expenses and strategic stock sales, while advancing key drug trials in cancer treatment.
The company's focus on innovative drug development in cancer immunotherapy presents opportunities for growth and partnerships.
Challenges lie in managing expenses, conducting rigorous clinical evaluations, and balancing financial decisions with strategic priorities.

Corvus Pharmaceuticals reports Q3 progress in oncology and immune diseases

Corvus Pharmaceuticals reported a net loss of $6 million in Q3 2023 but showcased progress on soquelitinib and potential in ITK inhibition for immune diseases.
The company's financial overview and upcoming milestones indicate a strategic focus on advancing pipeline candidates and exploring partnerships.
While facing challenges in managing expenses and balancing resources, Corvus Pharmaceuticals has opportunities to drive growth through positive trial results and strategic partnerships.

Corvus Pharmaceuticals advances pipeline with promising therapies and partnerships

Corvus Pharmaceuticals showcased financial improvements and progress in their pipeline programs during Q4 2023 earnings call.
The company's focus on ITK inhibition and orphan drug designation for soquelitinib highlight their commitment to innovative therapies.
While facing cash challenges, Corvus is actively seeking partnerships and advancing trials to capitalize on commercial and medical opportunities.

Corvus Pharmaceuticals reports improved financials and promising clinical advancements

Corvus Pharmaceuticals demonstrated improved financials and strong clinical progress in Q1 2024, supported by recent financing.
The company's focus on Soquelitinib and ciforadenant presents promising opportunities for growth and advancement in the oncology space.
Challenges lie in operational scalability, trial design complexities, and the need for clear patient criteria and efficacy benchmarks.

Corvus Pharmaceuticals reports strong Q2 performance and advances key drugs

Corvus Pharmaceuticals demonstrated financial stability and clinical progress in Q2 2024, with a strong cash position and promising pipeline.
The company's focus on selective ITK inhibition for immune diseases and cancer shows commitment to innovative therapies and addressing unmet medical needs.
While facing challenges in trial expectations and resource allocation, Corvus Pharmaceuticals has opportunities for growth through portfolio diversification and milestone achievements.
Overall, Corvus Pharmaceuticals is well-positioned to capitalize on its strengths, navigate challenges, and seize opportunities in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Cue Biopharma

Precigen

Sana Biotechnology

Ardelyx

Atossa Genetics

Bioline RX

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion Enrollment continues in Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma, including use of minimum absolute lymphocyte count (ALC) predictive biomarker for patient selection BURLINGAME, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company's ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action.

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.

The 3 Best Biotech Stocks Under $1 to Buy for April

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Mara Goldstein - Mizuho Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2022 Business Update and Financial Results Conference Call.

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript

New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

Results in patients with refractory T cell lymphoma demonstrated CPI-818's anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November 12, 2022. Dr. Rosenbaum received the ACR's second highest honor, for his outstanding contributions to rheumatology and care of patients.

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Jerry Gong - Mizuho Securities Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2022 Business Update and Financial Results Conference Call.

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript

Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium (KCRC) and is led by The University of Texas MD Anderson Cancer Center, one of seven partner institutions that make up the KCRC. The study is expected to enroll up to 60 patients at KCRC partner institutions.

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place September 12-14, 2022. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 12.

Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer James Rosenbaum - Senior President of Research Conference Call Participants Sean Lee - H.C. Wainwright Operator Good afternoon, and welcome to the Corvus Pharmaceutical Second Quarter 2022 Earnings Conference Call.

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call Transcript

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus will be to lead the development of CPI-818, the Company's ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases.

News for Corvus Pharmaceuticals Stock (CRVS)